TITLE

EMA RECOMMENDS XOMA 052 FOR BEUCET'S DISEASE AS ORPHAN DRUG

PUB. DATE
September 2010
SOURCE
Worldwide Biotech;Sep2010, Vol. 22 Issue 9, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the European Medicines Agency (EMA) Committee for Orphan Medical Products' adoption of a positive opinion and recommendation of the granting of orphan medicinal product designation for XOMA Ltd.'s XOMA 052, an antibody to interleukin-1 beta, to treat Behcet's disease. The designation's provision of European Union (EU) market exclusivity for the given indication is discussed. A study of Behcet's disease patients with uveitis showed that XOMA 052 reduced intraocular inflammation and improved visual acuity.
ACCESSION #
53281240

 

Related Articles

  • XOMA Inks $505M Servier Pact for IL-1 Inhibitor XOMA 052. Boggs, Jennifer // BioWorld Today;1/5/2011, Vol. 22 Issue 3, p1 

    The article reports on a structured ex-U.S. contract signed by XOMA Ltd. with Les Laboratoires Servier for interleukin-1 inhibitor XOMA 052. Experts believe that the partnership came ahead of the majority of expectations, since Phase II study results in Type II diabetes are not yet available....

  • XOMA REPORTS NET LOSS OF $13.6 MILLION FOR 3RD QTR 2010.  // Biotech Financial Reports;Dec2010, Vol. 17 Issue 12, p1 

    The article offers information on the business update and financial results of Xoma Ltd. for the third quarter of 2010 in Berkeley, California. It states that the company has reported a net loss of 13.6 million dollar due to increase research and development expenses. It also discusses the...

  • Parents for Orphans. O'Donnell, Peter // Applied Clinical Trials;May2002, Vol. 11 Issue 5, p34 

    Focuses on a guideline on the requirements for submission of application for a proposed orphan drug in the European Union. Revisions in the format and content of applications for designation of orphan products; Improvements in the marketing of medicinal product; Prevalence of a condition for...

  • Anakinra treatment in drug-resistant Behcet's disease: a case series. Cantarini, Luca; Vitale, Antonio; Scalini, Perla; Dinarello, Charles; Rigante, Donato; Franceschini, Rossella; Simonini, Gabriele; Borsari, Giulia; Caso, Francesco; Lucherini, Orso; Frediani, Bruno; Bertoldi, Ilaria; Punzi, Leonardo; Galeazzi, Mauro; Cimaz, Rolando // Clinical Rheumatology;Jul2015, Vol. 34 Issue 7, p1293 

    The study objective was to report treatment with an interleukin (IL)-1 receptor antagonist, anakinra, in patients with multiorgan Behcet's disease (BD). Comparison of clinical manifestations, previous treatments, markers of inflammation, concomitant medications, treatment regimen modifications,...

  • Importance of serum amyloid-A in Behçet's disease. Agilli, Mehmet; Aydin, Fevzi; Kurt, Yasemin; Cayci, Tuncer // Clinical Rheumatology;Feb2016, Vol. 35 Issue 2, p551 

    No abstract available.

  • Financings Roundup.  // BioWorld Today;6/8/2009, Vol. 20 Issue 108, p4 

    This article reveals the plan of XOMA Ltd. to raise $12 million in its second financing deal in less than a month. Particular focus is given to the terms of the agreement signed between XOMA and certain institutional investors. There is a plan to use proceeds from the financing deal to support...

  • Introducing the immunomodulatory effects of mesenchymal stem cells in an experimental model of Behçet’s disease. Mazaheri, Tina; Esmaeilzadeh, Abdolreza; Mirzaei, Mehri H.KH. // Journal of Medical Hypotheses & Ideas;Jan2012, Vol. 6 Issue 1, p23 

    Behçet’s disease (BD) is a systemic vasculitis which is characterised by oral, aphthous ulcers, genital ulcers, skin lesions and ocular manifestations. Although the aetiopathogenesis of BD is still unknown, the critical role of Th1 immune responses, neutrophil hyperactivation alongside...

  • IL-1 Blockers Gain Momentum As XOMA Partners Lead Drug. Morrison, Trista // BioWorld Insight;1/10/2011, Vol. 19 Issue 2, p3 

    The article discusses the potentials of the use of interleukin-1 (IL-1) inhibitor to treat autoimmune and inflammatory diseases such as rheumatoid arthritis. Because of the potentials of the IL-1, XOMA Ltd. focused its interest in XOMA 052 antibody which binds to the inhibitor to treat other...

  • XOMA's IL-1 Inhibitor Down and Out in Type II Diabetes. Shaffer, Catherine // BioWorld Today;3/24/2011, Vol. 22 Issue 57, p1 

    The article reports on the decline in stock of XOMA Ltd. following the news that its investigational interleukin-1 inhibitor, XOMA 052 did not achieve reduction of glycosylated hemoglobin (HbA1c) in a Phase IIb trial in Type II diabetes. According to chief executive officer (CEO) Steven Engle,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics